Non-exclusive rebate agreement for biosimilar active ingredients
Non-exclusive rebate agreements under § 130a Abs. 8 SGB V for biosimilar active ingredients: Contract start on 01.10.2026, open accession model for all interested companies under the same conditions. Submission of signed contracts/declarations and proofs by 10.09.2026 for an initial notification on 01.10.2026. Required documents: signed contract (duplicate or qualified electronic signature (QES)), proof of marketing authorization (excerpt from the public part of the AMIce database), list of contract-relevant PZN (Annex 5), signed self-declaration (Annex 6), self-declaration regarding EU regulation (Annex 7). Contract documents, participating health insurance funds, and their revenues are available on the GWQ ServicePlus AG procurement portal.
CONTRACTING AUTHORITY
Name
GWQ ServicePlus AG
City
Düsseldorf
Country
DE
CLASSIFICATION
Procedure Type
Open Procedure
Contract Type
Supplies
Main CPV
33600000, Pharmaceutical products.
LOTS (4)
Nicht-exklusive Rabattvereinbarung für den Wirkstoff Trastuzumab
Nicht-exklusive Rabattvereinbarung für den Wirkstoff Natalizumab (IFK)
Nicht-exklusive Rabattvereinbarung für den Wirkstoff Infliximab (i.v.)
Nicht-exklusive Rabattvereinbarung für den Wirkstoff Omalizumab
ADDITIONAL DETAILS
EU Funded
Yes
Suitable for SMEs
No
Electronic Submission
allowed
Legal Basis
32014L0024
DEADLINES & TIMELINE
Submission Deadline
372 days remaining(LOT-0001)
Published